Abstract
Despite the large range of drugs and surgical interventions, there is currently a significant number of patients with angina, in whom the surgery is impossible for various reasons, and drug therapy is not effective enough. In contrast to these methods of treating coronary heart disease and its complications, cell cardiomyoplasty is aimed at creating new cells and stable lineages of normally functioning heart tissue. Autologous bone marrow mesenchymal stem cells are the promising source for such a cardiomyoplasty. To improve the treatment results in the patients suffered from coronary heart disease with refractory angina and heart failure, there was comparatively studied the effect of intravenous administration of autologous mesenchymal bone marrow stem cells on the effectiveness of myocardial remodeling at months 3 and 6, that was assessed by stenocardiography and echocardiography insufficiency, indices of quality of life and tolerance to physical activity. As a result, it was reliably established that the patients receiving autologous cell therapy in combination with traditional methods had a reduced incidence of anginal attacks, decreased functional class of heart failure and angina, improved left ventricular contractile function, improved exercise tolerance and quality of life. Thus, intravenous administration of autologous bone marrow mesenchymal stem cells to patients with chronic ischemic disease, which is manifested in refractory angina and complicated by heart failure is a safe alternative to other treatments and has its advantages. There has been an improvement in the heart pumping function and the life quality of patients. Key words: cardiomyoplasty, stem cells, heart failure, refractory angina.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call